Supplementary Figure S4 from First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors

Genes differentially expressed as a function of BOR on day 8. (A) Linear discriminant analysis of Log2 fold change in expression levels of 780 genes in patients stratified based on BOR. PR: partial response; SD: stable disease; PD: progressive disease. (B) Genes that maximally discriminate between PR and PD patients enrolled in combination therapy arm. * p<0.05 by Mann-Whitney U-test.